I've had a look around, Edison, allowing for the market penetration and effectiveness of Entresto still rate Resvascor, subject to P3 results as around US $2 billion US annual sales (plus about half that again in the EU). Some of their analysis is based on this proviso;
"Use of MPC therapy will be concentrated in those who do not respond adequately to Entresto and who may be undergoing a catheter procedure anyway."
From page 15 in;
https://www.edisongroup.com/wp-content/uploads/2019/10/Mesoblast-Increasingly-positive-on-aGvHD.pdf
Clearly Entresto has revolutionised treatment but it seems there is quite enough space
Coming up to the end of February, not too many more months to wait for a clearer direction.
MSB, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |